Abpro (ABP) Competitors $0.22 +0.02 (+10.10%) As of 11:07 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ABP vs. ATNM, PRLD, GRCE, LIAN, NBRV, XCUR, OSTX, RANI, SCLX, and LTRNShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include Actinium Pharmaceuticals (ATNM), Prelude Therapeutics (PRLD), Grace Therapeutics (GRCE), LianBio (LIAN), Nabriva Therapeutics (NBRV), Exicure (XCUR), OS Therapies (OSTX), Rani Therapeutics (RANI), Scilex (SCLX), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Its Competitors Actinium Pharmaceuticals Prelude Therapeutics Grace Therapeutics LianBio Nabriva Therapeutics Exicure OS Therapies Rani Therapeutics Scilex Lantern Pharma Actinium Pharmaceuticals (NYSE:ATNM) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk. Do insiders & institutionals believe in ATNM or ABP? 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 20.8% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to ATNM or ABP? In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled Abpro'saverage media sentiment score. Company Overall Sentiment Actinium Pharmaceuticals Neutral Abpro Neutral Do analysts prefer ATNM or ABP? Actinium Pharmaceuticals currently has a consensus target price of $4.00, indicating a potential upside of 133.24%. Abpro has a consensus target price of $4.00, indicating a potential upside of 1,681.74%. Given Abpro's stronger consensus rating and higher probable upside, analysts clearly believe Abpro is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actinium Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, ATNM or ABP? Abpro has higher revenue and earnings than Actinium Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActinium PharmaceuticalsN/AN/A-$48.82M-$1.47-1.17Abpro$183K74.57-$7.23MN/AN/A Is ATNM or ABP more profitable? Abpro's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Actinium PharmaceuticalsN/A -100.85% -47.89% Abpro N/A N/A -198.95% SummaryAbpro beats Actinium Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.65M$2.93B$5.51B$9.47BDividend YieldN/A2.48%4.00%4.04%P/E RatioN/A20.0028.1819.90Price / Sales74.57235.57426.8892.15Price / CashN/A40.8024.9928.17Price / Book-0.777.768.275.77Net Income-$7.23M-$55.16M$3.24B$257.79M7 Day Performance13.44%3.31%1.80%2.77%1 Month Performance7.57%15.60%9.32%14.17%1 Year PerformanceN/A5.92%35.12%20.71% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbproN/A$0.22+10.1%$4.00+1,681.7%N/A$13.65M$183K0.0015ATNMActinium Pharmaceuticals2.1817 of 5 stars$1.52-3.5%$4.00+164.0%N/A$47.26MN/A-1.0930PRLDPrelude Therapeutics3.6145 of 5 stars$0.81-0.5%$4.50+452.2%-84.4%$46.24M$7M-0.48120GRCEGrace Therapeutics1.7184 of 5 stars$3.19-3.6%$12.00+276.2%N/A$45.77MN/A-3.58N/APositive NewsLIANLianBioN/A$0.42-0.9%N/A-82.8%$45.68MN/A-0.52110NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070XCURExicure0.8672 of 5 stars$6.85-2.6%N/A+1,382.0%$44.41M$500K-1.7950OSTXOS Therapies2.5142 of 5 stars$1.58+1.3%$18.00+1,039.2%N/A$44.40MN/A-1.84N/ARANIRani Therapeutics2.3446 of 5 stars$0.43-38.4%$7.33+1,605.4%-86.5%$44.14M$1.03M-0.43110High Trading VolumeSCLXScilex1.9686 of 5 stars$6.73+6.5%$455.00+6,660.8%-85.5%$43.93M$56.59M-0.2380Gap DownLTRNLantern Pharma2.841 of 5 stars$3.76-5.8%$25.00+564.9%-9.5%$43.03MN/A-2.0420News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies ATNM Alternatives PRLD Alternatives GRCE Alternatives LIAN Alternatives NBRV Alternatives XCUR Alternatives OSTX Alternatives RANI Alternatives SCLX Alternatives LTRN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
